

AVANIR PHARMACEUTICALS, INC.

Form 8-K

November 28, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 26, 2014**

**Avanir Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-15803**  
**(Commission**

**File Number)**

**33-0314804**  
**(I.R.S. Employer**

**Identification No.)**

**30 Enterprise, Suite 400, Aliso Viejo, California**

**92656**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (949) 389-6700**

**Not Applicable**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On November 26, 2014, Avanir Pharmaceuticals, Inc. (the Company ) issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response letter to its New Drug Application for AVP-825. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit

No.	Description
99.1	Press Release, dated November 26, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 26, 2014

Avanir Pharmaceuticals, Inc.

By: /s/ Christine G. Ocampo  
Christine G. Ocampo  
Vice President, Chief Accounting Officer

**Exhibit Index**

Exhibit

No.	Description
99.1	Press Release, dated November 26, 2014